{
    "clinical_study": {
        "@rank": "16821", 
        "arm_group": [
            {
                "arm_group_label": "NNC 0151-0000-0000 i.v.", 
                "arm_group_type": "Experimental", 
                "description": "Dose escalation trial"
            }, 
            {
                "arm_group_label": "NNC 0151-0000-0000 s.c.", 
                "arm_group_type": "Experimental", 
                "description": "Dose escalation trial"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of this trial is to develop a complement system\n      targeted monoclonal antibody (mAb) to be used in treatment of subjects with chronic\n      autoimmune diseases."
        }, 
        "brief_title": "Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects", 
        "completion_date": {
            "#text": "October 2009", 
            "@type": "Actual"
        }, 
        "condition": [
            "Inflammation", 
            "Systemic Lupus Erythematosus", 
            "Rheumatoid Arthritis", 
            "Healthy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid", 
                "Inflammation", 
                "Lupus Erythematosus, Systemic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent obtained before any trial-related activities (Trial-related\n             activities are any procedure that would not have been performed during normal\n             management of the subject)\n\n          -  Body weight (BW) below or equal to 110.0 kg\n\n          -  Body Mass Index (BMI) 20.0 - 27.0 kg/m^2, both inclusive\n\n          -  Good state of health: evidenced by medical history, physical examination and results\n             of laboratory examinations\n\n        Exclusion Criteria:\n\n          -  History of known or suspected cardiovascular diseases including: supine systolic\n             blood pressure (BP) above or equal to 140 mmHg or below  90 mm Hg, diastolic BP above\n             oe equal to 90 mm Hg or below 40 mm Hg, heart rate (HR) in supine position above 100\n             beats/minute or below 45 beats/minute\n\n          -  Hepatic insufficiency: Alanine aminotransferase (ALT) or aspartate aminotransferase\n             (AST) above Upper Limit of Normal (ULN) (retesting is permitted within one week if\n             first test is elevated but below 1.5 fold ULN)\n\n          -  Renal insufficiency: Serum creatinine above ULN\n\n          -  Positive for humane immunodeficiency virus (HIV) (by test)\n\n          -  Positive for hepatitis B (HBV) or hepatitis C (HCV) (by test)"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02151409", 
            "org_study_id": "NN8209-1940", 
            "secondary_id": "2008-000731-18"
        }, 
        "intervention": [
            {
                "arm_group_label": "NNC 0151-0000-0000 i.v.", 
                "description": "A single dose (SD), administrated i.v. (intravenous) at 8 dose levels.", 
                "intervention_name": "NNC 0151-0000-0000", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "NNC 0151-0000-0000 s.c.", 
                "description": "A single dose (SD), administrated s.c. (subcutaneously) at 7 dose levels", 
                "intervention_name": "NNC 0151-0000-0000", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "A single dose (SD), administrated i.v. (intravenous) or s.c. (subcutaneously).", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 28, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Zuidlaren", 
                    "country": "Netherlands", 
                    "zip": "9471 GP"
                }
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Trial of Anti-C5aR Antibody (NNC 0151-0000-0000) Administered by i.v. Infusion or s.c. Injection in Healthy Subjects.", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Netherlands: Dutch Health Care Inspectorate", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Adverse events (AEs)", 
            "safety_issue": "No", 
            "time_frame": "Week 0-10"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02151409"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}